AHR and pulmonary arterial hypertension: Whereas the chemopreventive potential of AHR antagonists against PAH-induced skin cancers is mainly due to a decrease in CYP1A enzyme activity and associated metabolic activation, these compounds may alter ECM remodeling, DNA repair and apoptosis to prevent or delay skin wrinkling and photocarcinogenesis.